Merck Earnings|Guidance Tuesday, August 4, 2026 +0.50 Positive

Merck Q2 2026 Sales Jump 5% to $16.6B

Merck posted strong Q2 2026 sales growth led by oncology and a new launch, also narrowing full-year guidance excluding acquisition costs.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day